Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Effect of Stellate Ganglion Block on Sleep Quality in Patients With Depression

8 octobre 2026 mis à jour par: Li Juan

# Brief Summary

This clinical research study looks at whether stellate ganglion block (SGB) can improve sleep quality for people with depression. Poor sleep often goes together with depression. Medicines used for these conditions may cause side-effects or dependency. Researchers want to learn if SGB, a minimally-invasive nerve treatment, can help sleep and mood without those medicine-related downsides.

This study uses a self-controlled design. Every person who joins will receive the study treatment. No separate comparison group is enrolled. Researchers will collect sleep data from each participant before treatment and again after treatment, then compare these two sets of information.

About 42 participants will take part in this study.

Key requirements to join the study:

  • Aged 18 to 65 years old
  • Have depression-related symptoms and sleep trouble
  • Able to understand and sign an informed consent form
  • No medical conditions that make SGB unsafe
  • Have not taken sleep-affecting medicines or received other sleep-focused treatments in the past one month
  • Can follow study schedules and complete all study assessments

People cannot join if they:

  • Are younger than 18 years or older than 65 years
  • Are pregnant or breastfeeding
  • Have known allergies to study-used medicines
  • Have unstable serious organ diseases, uncontrolled substance or alcohol dependence
  • Cannot keep fixed daily routines or finish all study visits

Study procedures for each participant:

  1. On study day zero (D0): Study staff will explain the study fully. Participants will sign informed consent. Staff will run physical checks and blood tests. Participants will fill out several simple questionnaires about mood and sleep. Sleep will be measured overnight with a multi-channel sleep recording device called polysomnography (PSG). Participants also keep a short sleep diary.
  2. From study day one (D1) to day five (D5): Participants get one SGB treatment each day, for a total of five treatments. During SGB, a doctor uses ultrasound guidance to inject small-dose local anesthetic near nerves in the neck. Participants keep completing their sleep diary every day. Study staff watch for any unwanted reactions during each treatment.
  3. On the night of D5 through early morning of D6: PSG sleep recording will be repeated after the final SGB treatment.
  4. On study day six (D6): Participants finish the final set of mood-and-sleep questionnaires. Study staff collect all safety information.

Researchers will compare sleep measurements taken before treatment versus after five-day SGB treatment. Collected data includes objective sleep readings from PSG and self-reported sleep information from sleep diaries. Questionnaires will show changes in depression and insomnia symptoms.

Possible benefits: SGB may make participants' sleep better and may ease depression-related symptoms. No benefit is guaranteed for every participant.

Possible risks: SGB is generally safe. Rare unwanted reactions may include temporary hoarseness, local neck-site infection, or drug allergic responses. Study doctors will watch participants closely. If serious problems happen, immediate medical help will be provided.

All participants' private personal information will be protected. Participants can choose to stop taking part in this research at any time without penalty.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Estimé)

42

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 65 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Aged 18-65 years of both genders. Alert and capable of normal communication. Voluntarily sign informed consent, complete the whole experimental procedure, and meet ethical and compliance requirements.
  2. Hamilton Depression Rating Scale (HAMD) score ≥ 8.
  3. Insomnia Severity Index (ISI) score ≥ 7 or Pittsburgh Sleep Quality Index (PSQI) score ≥ 7.
  4. No contraindications to stellate ganglion block (SGB); no cervical deformity, trauma, or infection; and no severe cervical spine disease, such as cervical fracture or cervical disc herniation with nerve compression.
  5. No use of sedative-hypnotics, anxiolytics, antidepressants, or other medications that may affect sleep within the past month, and no acupuncture, massage, nerve block, or other sleep-related interventions during the same period.
  6. Stable vital signs; normal liver and renal function, complete blood count, and coagulation function; and no severe organic diseases of the heart, brain, lungs, liver, or kidneys.
  7. Able to strictly follow the required sleep-wake schedule and cooperate with polysomnography (PSG) monitoring and completion of sleep diaries, with good study compliance.

Exclusion Criteria:

  • 1: Age <18 or >65 years; pregnant or lactating women; subjects with psychiatric disorders (schizophrenia, mania, etc.) or cognitive impairment who cannot cooperate with the study, to prevent missing data and experimental bias.

    2: Presence of contraindications to stellate ganglion block, such as coagulation disorders, local skin infection, severe cervical spine disease, hyperthyroidism, glaucoma, or increased intracranial pressure.

    3: Allergy to ropivacaine, epinephrine, or other drugs used for the block, or a history of drug allergy.

    4: Use of sedative-hypnotics, anxiolytics, antidepressants, hormonal medications, or other treatments that may affect sleep within the past month.

    5: Severe cardiovascular or cerebrovascular disease, hepatic or renal insufficiency, hematologic disease, respiratory disease, or other serious organic diseases, or a recent history of surgery or trauma.

    6: Alcohol dependence or drug dependence, or daily consumption of coffee, strong tea, or other stimulating beverages with inability to abstain during the study period.

    7: Inability to maintain a fixed sleep-wake schedule during the study or inability to complete the full monitoring and intervention procedures because of work, daily life, or other reasons.

    8: Voluntary withdrawal during the study, or inability to complete the study because of adverse reactions, poor compliance, or other reasons.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: SGB group

Stellate Ganglion Block

Using an anterior-lateral approach, participants lie supine with head turned contralaterally to expose the neck. The interspace between the anterior sternocleidomastoid border, trachea and common carotid artery is identified. Skin is disinfected 3 times with iodophor (≥15 cm diameter), then covered with a sterile aperture drape.

A 22-G needle is inserted vertically at the target site. After bony contact with the C6 transverse process, the needle is retracted 0.1-0.2 cm. With negative aspiration for blood and cerebrospinal fluid, inject 6 mL 0.25% ropivacaine (epinephrine 1:200 000) at 1 mL/min to limit bleeding and prolong block effect.

Monitor blood pressure, heart rate, oxygen saturation, and adverse events (hoarseness, Horner syndrome, dyspnea) throughout injection.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Délai
Sleep Onset Latency, SOL
Délai: At baseline (Day 0) and from Night 5 to Morning 6 after intervention
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
Wake After Sleep Onset, WASO
Délai: At baseline (Day 0) and from Night 5 to Morning 6 after intervention
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
Total Sleep Time, TST
Délai: At baseline (Day 0) and from Night 5 to Morning 6 after intervention
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
Proportions of each non-rapid eye movement sleep stage
Délai: At baseline (Day 0) and from Night 5 to Morning 6 after intervention
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
Proportions of REM, NREM and Wake
Délai: At baseline (Day 0) and from Night 5 to Morning 6 after intervention
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
Sleep Efficiency, SE
Délai: At baseline (Day 0) and from Night 5 to Morning 6 after intervention
At baseline (Day 0) and from Night 5 to Morning 6 after intervention

Mesures de résultats secondaires

Mesure des résultats
Délai
Subjective sleep-onset latency
Délai: 30 minutes after awakening on the corresponding next morning
30 minutes after awakening on the corresponding next morning
Subjective Total Sleep Time
Délai: 30 minutes after awakening on the corresponding next morning
30 minutes after awakening on the corresponding next morning
Subjective Sleep Efficiency
Délai: 30 minutes after awakening on the corresponding next morning
30 minutes after awakening on the corresponding next morning
Sleep Satisfaction
Délai: 30 minutes after awakening on the corresponding next morning
30 minutes after awakening on the corresponding next morning

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

20 septembre 2026

Achèvement primaire (Estimé)

1 décembre 2026

Achèvement de l'étude (Estimé)

30 décembre 2026

Dates d'inscription aux études

Première soumission

7 septembre 2026

Première soumission répondant aux critères de contrôle qualité

17 septembre 2026

Première publication (Réel)

23 septembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

8 octobre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • BoYi Medical Ethics No.1162026

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified individual participant data underlying the published results will be available to qualified researchers after article publication. Data access requires a formal research proposal and signed data-use agreement.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .